news
Sanofi and GSK to supply UK with 60 million doses of COVID-19 vaccine
Sanofi and GSK have reached an agreement with the UK government to supply up to 60 million doses of their COVID-19 vaccine.
List view / Grid view
Vaccines
webinar
The analytical reality of recombinant endotoxin technologies
29 July 2020 | By Charles River
In this webinar we discuss the results of our latest study where we evaluated the ruggedness, repeatability and specificity of commercially available rFC products, as well as our own recombinant product in development, against a large panel of endotoxins.
news
Pfizer and BioNTech COVID-19 vaccine candidate enters Phase II/III trials
The BNT162b2 mRNA-based vaccine produced by Pfizer and BioNTech will enter Phase have II/III clinical trials to test its safety and efficacy against COVID-19.
news
UK government invests £100 million into COVID-19 vaccine manufacturing
The UK government has committed £100 million to establish a centre to scale up COVID-19 vaccine and gene therapy manufacturing.
news
FUJIFILM Diosynth Biotechnologies to manufacture Novavax COVID-19 vaccine candidate
Novavax and FUJIFILM Diosynth Biotechnologies have agreed for FDB to make the bulk drug substance for NVX-CoV2373, the Novavax COVID-19 vaccine candidate.
video
On-demand webinar: Key challenges to select media for media fill tests
Watch our quick learning and learn in only 10 minutes what key challenges manufacturers are facing when selecting media for media fill tests and how to overcome them.
news
EMA to monitor real world use of COVID-19 treatments and vaccines
The EMA has built up an infrastructure to allow for the monitoring of COVID-19 treatments and vaccines used in clinical practice.
news
Pfizer and BioNTech to supply up to 600 million doses of COVID-19 vaccine to US
An agreement between the US government and Pfizer and BioNTech will have the companies produce an initial 100 million doses of their COVID-19 vaccine candidate, with the potential for 500 million more.
news
Plant-based COVID-19 vaccine enters Phase I trials
The vaccine containing a recombinant coronavirus virus-like particles (CoVLP) will be tested in three different doses and with two different adjuvants.
news
UK’s SARS-CoV-2 vaccine candidate is safe and induces antibody and T cell response
Data released from the Phase I/II trial of the ChAdOx1 COVID-19 vaccine candidate suggests it elicits an immune response with no adverse effects.
news
COVID-19 vaccine safely induces immune response in Chinese trial
Investigators report CanSino Biologics’ Ad5-nCoV vaccine induced antibody production with mild to moderate side effects in patients.
news
UK government secures early access to 90 million doses of COVID-19 vaccines
The government has entered partnerships with Pfizer and Valneva to secure doses of several promising COVID-19 vaccines and secured COVID-19 neutralising antibody treatments from AstraZeneca.
news
Johnson & Johnson to start COVID-19 vaccine trials next week
The company will start enrolment to the Ad26.COV2-S vaccine trial next week, it anticipates initial results in September.
article
Outsourcing update: the latest developments in pharma
European Pharmaceutical Review explores some of the latest developments in outsourcing, including clinical development and production agreements; acquisitions and collaborations; and expansions.
news
Experimental COVID-19 vaccine mRNA-1273 is safe and elicits response
Interim analysis of the Phase I trial data from 45 patients indicates mRNA-1273 can drive the production of antibodies targeting the SARS-CoV-2 spike protein.
